phd student, Swinburne university of technology
Im working on mathematical experiments on different methods for cancer therapy
Using some system of equations which illustrates the interaction among tumor cells and immune cells in the body, we try to predict how useful a treatment will be and propose some idea to improve the treatment. We studied chemotherapy and electro-magno-therapy by now and the results have been published in high reputation journals in this field. Now I am working in a more detailed view to study the real interaction among cells without too much simplifying assumption to get more realistic results.
Abstract: chemotherapy is usually known as the main modality for cancer treatment. Nevertheless, most of chronic cancers could not be treated with chemotherapy alone. Immunotherapy is a new modality for cancer treatment that is effective for early stages of cancer and it has fewer side effects compared to chemotherapy, specifically for those types of cancer that are resistant to it.This work presents an extended mathematical model to depict interactions between cancerous and adaptive immune system in mouse. We called the model an extended model, because we embedded all those compartments that have important roles in response to tumor in one model. The model includes tumor cells, natural killers, naïve and mature cytotoxic T cells, naïve and mature helper T cells, regulatory T cells, dendritic cells and interleukin 2 cytokine. Whole cycle of cell division program of immune cells is also considered in the model. We also optimized protocol of immunotherapy with DC vaccine based on the proposed mathematical model.Simulation results of the proposed model are in conformity with the experimental data recorded from mouse in immunology department of Tehran University of Medical Science as well as what has been explained in the literature. Our results explain dynamics of the immune cells from the first day of cancer growth and progression. Simulation result shows that reducing intervals between immunotherapy injections, efficacy of the treatment will be increased because CD8+ cells are boosted more rapidly. Optimized protocol for immunotherapy suggests that if the effect of DC vaccines on increasing number of anti-tumor immune cells be just before the maximum number of CD8+ cells, the effect of treatment will be maximized.
Pub.: 18 Jul '17, Pinned: 23 Aug '17
Abstract: We studied the effect of low-power laser on the growth of human gastric adenocarcinoma transplanted to athymic mice. Irradiation shortened the latency of tumor growth in recipients from 4-6 months to 21-24 days. After 17 serial passages on athymic mice, the size of tumor node in irradiated recipients on day 33 after transplantation was 161.1 mm3 (vs. 10.2 mm3 in nonirradiated mice). These findings suggest that low-power laser irradiation can stimulate the growth of metastases in patients with a history of malignancy.
Pub.: 01 Aug '01, Pinned: 23 Aug '17
Abstract: The proposed model describes the interaction among normal, immune and tumor cells in a tumor with a chemotherapeutic drug, using a system of four coupled partial differential equations. The dimensions of the tumor and initial conditions of tumor cells are chosen under the assumption that the tumor is already large enough in size to be detectable with the available clinical devices. The pattern of distribution of tumor cells is drafted on the basis of clinical observations. The stability of the system is established with tumor and tumor-free equilibria. The process of tumor regression with the introduction of different diffusion coefficients of tumor and immune cells is considered along with normal cells of tissue without any diffusive movement. It is shown that the results of chemotherapy treatment are in agreement with Jeff’s phenomenon. The response of three different levels of immune system strength to the pulsed chemotherapy are investigated. It is observed that the tumor performs better if a chemotherapeutic drug is injected near the invasive fronts of the tumor.
Pub.: 30 Mar '17, Pinned: 23 Aug '17